Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2016

Open Access 01-12-2016 | Research article

Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review

Authors: Igho J. Onakpoya, Carl J. Heneghan, Jeffrey K. Aronson

Published in: BMC Medicine | Issue 1/2016

Login to get access

Abstract

Background

We identified anti-obesity medications withdrawn since 1950 because of adverse drug reactions after regulatory approval, and examined the evidence used to support such withdrawals, investigated the mechanisms of the adverse reactions, and explored the trends over time.

Methods

We conducted searches in PubMed, the World Health Organization database of drugs, the websites of drug regulatory authorities, and selected full texts, and we hand searched references in retrieved documents. We included anti-obesity medications that were withdrawn between 1950 and December 2015 and assessed the levels of evidence used for making withdrawal decisions using the Oxford Centre for Evidence-Based Medicine criteria.

Results

We identified 25 anti-obesity medications withdrawn between 1964 and 2009; 23 of these were centrally acting, via monoamine neurotransmitters. Case reports were cited as evidence for withdrawal in 80% of instances. Psychiatric disturbances, cardiotoxicity (mainly attributable to re-uptake inhibitors), and drug abuse or dependence (mainly attributable to neurotransmitter releasing agents) together accounted for 83% of withdrawals. Deaths were reportedly associated with seven products (28%). In almost half of the cases, the withdrawals occurred within 2 years of the first report of an adverse reaction.

Conclusions

Most of the drugs that affect monoamine neurotransmitters licensed for the treatment of obesity over the past 65 years have been withdrawn because of adverse reactions. The reasons for withdrawal raise concerns about the wisdom of using pharmacological agents that target monoamine neurotransmitters in managing obesity. Greater transparency in the assessment of harms from anti-obesity medications is therefore warranted.
Appendix
Available only for authorised users
Literature
1.
2.
Cawley J, Meyerhoefer C, Biener A, Hammer M, Wintfeld N. Savings in medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status. Pharmacoeconomics. 2015;33(7):707–22.CrossRefPubMed
3.
4.
5.
Dietz WH, Baur LA, Hall K, Puhl RM, Taveras EM, Uauy R, Kopelman P. Management of obesity: improvement of health-care training and systems for prevention and care. Lancet. 2015;385(9986):2521–33.CrossRefPubMed
6.
Tainter ML, Stockton AB, Cutting WC. Use of dinitrophenol in obesity and related conditions. A progress report. JAMA. 1933;101:1472–5.CrossRef
7.
Grundlingh J, Dargan PI, El-Zanfaly M, Wood DM. 2,4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death. J Med Toxicol. 2011;7(3):205–12.CrossRefPubMedPubMedCentral
8.
9.
Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med. 2005;143(5):380–5.CrossRefPubMed
10.
Council of Pharmacy and Chemistry of the American Medical Association. New and nonofficial remedies. Philadelphia: JB Lippincott; 1946. p. 281.
11.
Bray GA. Medical treatment of obesity: the past, the present and the future. Best Pract Res Clin Gastroenterol. 2014;28(4):665–84.CrossRefPubMed
12.
13.
Daneschvar HL, Aronson MD, Smetana GW. FDA Approved Anti-obesity Drugs in the United States. Am J Med. 2016;129(8):879. e1–6.CrossRefPubMed
14.
15.
16.
17.
18.
19.
Hainer V, Aldhoon-Hainerová I. Tolerability and safety of the new anti-obesity medications. Drug Saf. 2014;37(9):693–702.CrossRefPubMed
20.
21.
Aagaard L, Hallgreen CE, Hansen EH. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance. Int J Obes (Lond). 2016. doi:10.​1038/​ijo.​2016.​135.
22.
de Angelis L. 5-HT2A antagonists in psychiatric disorders. Curr Opin Investig Drugs. 2002;3(1):106–12.PubMed
23.
Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000;102(23):2836–41.CrossRefPubMed
24.
Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014;95(1):53–66.CrossRefPubMed
25.
Hodgkins P, Shaw M, Coghill D, Hechtman L. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry. 2012;21(9):477–92.CrossRefPubMedPubMedCentral
26.
27.
28.
Lawlor DA, Chaturvedi N. Treatment and prevention of obesity—are there critical periods for intervention? Int J Epidemiol. 2006;35(1):3–9.CrossRefPubMed
29.
Look AHEAD. Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.CrossRef
30.
Charakida M, Finer N. Drug treatment of obesity in cardiovascular disease. Am J Cardiovasc Drugs. 2012;12(2):93–104.CrossRefPubMed
31.
32.
33.
Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–77.CrossRefPubMed
34.
Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56.CrossRefPubMed
35.
O’Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–36.CrossRef
36.
37.
38.
Miller LE. Lorcaserin for weight loss: insights into US Food and Drug Administration approval. J Acad Nutr Diet. 2013;113(1):25–30.CrossRefPubMed
39.
Woloshin S, Schwartz LM. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? JAMA Intern Med. 2014;174(4):615–9.CrossRefPubMed
40.
No authors listed. Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss. Prescrire Int. 2015;24(164):229–33.
41.
42.
Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, Perez A, Smith SR. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315(10):990–1004.CrossRefPubMed
43.
Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance—lack of vigilance, lack of trust. JAMA. 2004;292(21):2647–50.CrossRefPubMed
44.
45.
46.
Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289(12):1537–45.PubMed
47.
Food and Drug Administration, HHS. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Fed Regist. 2004;69(28):6787–854.
48.
Abraham J. Science, politics, and the pharmaceutical industry: controversy and bias in drug regulation. New York: St. Martin’s Press; 1995.
49.
50.
51.
52.
Fishman AP. Aminorex to fen/phen: an epidemic foretold. Circulation. 1999;99(1):156–61.
53.
Fournier A, Zureik M. Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France. Pharmacoepidemiol Drug Saf. 2012;21(4):343–51.
54.
Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581–8.
55.
Ladewig D, Battegay R. Abuse of anorexics with special reference to newer substances. Int J Addict. 1971;6(1):167–72.
56.
Price K. Case notes: phentermine. Bull Int Assoc Foren Toxicol. 1974;10(1):12.
57.
Gadde KM. Effect of rimonabant on weight and cardiometabolic risk factors. JAMA. 2006;296(6):649–50; author reply 650–1.
58.
59.
Anonymous. Italy suspends sibutramine licence. Pharm J. 2002;268(7190):385–91.
60.
Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ. 2002;166(10):1307–8.
Metadata
Title
Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review
Authors
Igho J. Onakpoya
Carl J. Heneghan
Jeffrey K. Aronson
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2016
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-016-0735-y

Other articles of this Issue 1/2016

BMC Medicine 1/2016 Go to the issue

Review

Research impact: a narrative review

Commentary

Infectious diseases epidemic threats and mass gatherings: refocusing global attention on the continuing spread of the Middle East Respiratory syndrome coronavirus (MERS-CoV)

Commentary

(R)evolution: toward a new paradigm of policy and patient advocacy for expanded access to experimental treatments

Research article

Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: a time series analysis

Opinion

Immuno-psychiatry: an agenda for clinical practice and innovative research

Commentary

The efficiency of chronic disease care in sub-Saharan Africa